Hemolysis: Clinical Trials

10 trials for Hemolysis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed. 10 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 210Completed 10
Phase 31Completed 1

Follow Hemolysis: new trials by email Literature Review of Hemolysis trials Research Report on Hemolysis

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
Etavopivat tablets - Sickle Cell Disease, Thalassemia
Phase 2CompletedForma Therapeutics, Inc.532022-03-282025-12-16
Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria
LNP023 - Paroxysmal Nocturnal Hemoglobinuria
Phase 2CompletedNovartis Pharmaceuticals132019-04-052024-06-18
A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH
Pegcetacoplan - PNH
Phase 2CompletedApellis Pharmaceuticals, Inc.42018-08-162020-12-22
Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
iptacopan, Standard of Care - Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis
Phase 2CompletedNovartis Pharmaceuticals162018-04-092024-06-12
Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease
Bendamustine, Rituximab - Cold Agglutinin Disease, Autoimmune Hemolytic Anemia
Phase 2CompletedHelse Fonna432013-01-012017-01-09
Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease
Conditioning Regimen with Bone Marrow Transplant - Sickle Cell Disease
Phase 2CompletedEmory University222012-03-012017-11-21
Therapy of Chronic Cold Agglutinin Disease With Eculizumab
Eculizumab - Cold Agglutinin Disease
Phase 2CompletedUniversity Hospital, Essen132011-01-012017-07-19
Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias
Alemtuzumab, Rituximab - Idiopathic Thrombocytopenic Purpura, Anemia, Hemolytic, Autoimmune
Phase 2 / Phase 3CompletedHospital Universitario Dr. Jose E. Gonzalez192008-08-012010-08-30
S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C
Peginterferon alfa-2a, Ribavirin, S-adenosyl methionine for Chronic Liver Disease - Chronic Hepatitis C
Phase 2CompletedNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)242007-05-012013-07-05
Therapy for Chronic Cold Agglutinin Disease
Rituximab, Fludarabine - Cold Agglutinin Disease
Phase 2CompletedUniversity of Bergen302005-06-012010-06-22

Narrower conditions

Anemia (6)  ·  Anemia, Hemolytic, Autoimmune (4)  ·  Hematologic Diseases (3)  ·  Hemoglobinuria, Paroxysmal (3)  ·  Anemia, Sickle Cell (2)  ·  Genetic Diseases, Inborn (2)  ·  Anemia, Hemolytic (1)  ·  Hemoglobinopathies (1)  ·  Hemoglobinuria (1)  ·  Hepatitis C (1)  ·  Hepatitis C, Chronic (1)  ·  Lymphoproliferative Disorders (1)  ·  Purpura, Thrombocytopenic, Idiopathic (1)  ·  Sickle Cell Trait (1)

Broader conditions

Pathologic Processes (10)  ·  Pathological Conditions, Signs and Symptoms (10)  ·  Hemic and Lymphatic Diseases (9)  ·  Anemia, Hemolytic (8)  ·  Hematologic Diseases (6)  ·  Autoimmune Diseases (4)  ·  Immune System Diseases (4)  ·  Anemia (3)  ·  Bone Marrow Diseases (3)  ·  Myelodysplastic Syndromes (3)  ·  Anemia, Hemolytic, Congenital (2)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Signs and Symptoms (2)  ·  Blood Coagulation Disorders (1)  ·  Blood Platelet Disorders (1)

Interventions

Rituximab (3)  ·  fludarabine (2)  ·  iptacopan (2)  ·  Alemtuzumab (1)  ·  Antilymphocyte Serum (1)  ·  Bendamustine Hydrochloride (1)  ·  Bone Marrow Transplantation (1)  ·  Busulfan (1)  ·  Ribavirin (1)  ·  S-Adenosylmethionine (1)  ·  Standard of Care (1)  ·  Transplantation Conditioning (1)  ·  eculizumab (1)  ·  fludarabine phosphate (1)  ·  pegcetacoplan (1)

Sponsors

Novartis Pharmaceuticals (2)  ·  Apellis Pharmaceuticals, Inc. (1)  ·  Emory University (1)  ·  Forma Therapeutics, Inc. (1)  ·  Helse Fonna (1)  ·  Hospital Universitario Dr. Jose E. Gonzalez (1)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)  ·  University Hospital, Essen (1)  ·  University of Bergen (1)

Countries

United States (3)  ·  Germany (2)  ·  Italy (2)  ·  Norway (2)  ·  Bulgaria (1)  ·  Canada (1)  ·  Denmark (1)  ·  Egypt (1)  ·  Finland (1)  ·  France (1)  ·  Lebanon (1)  ·  Malaysia (1)  ·  Mexico (1)  ·  Russia (1)  ·  Serbia (1)

Top investigators

Geir E Tjonnfjord, MD, PhD (2)  ·  Sigbjorn Berentsen, MD, PhD (2)  ·  Alexander Roeth, MD (1)  ·  David Gomez-Almaguer, MD (1)  ·  Elling Ulvestad, MD, PhD (1)  ·  Federico Grossi, MD, PhD (1)  ·  Henrik Birgens, MD, PhD (1)  ·  Jay Hoofnagle, MD (1)  ·  Lakshmanan Krishnamurti, MD (1)  ·  Markku Oksman, MD (1)

Results publications

PMID 20634373, PMID 20841509, PMID 20854821, PMID 28533306, PMID 30291112, PMID 33765419, PMID 35561315, PMID 35869170

NIH funding

2009 (1), 2017 (1), R34HL108761 (1)